Us Congress 2023-2024 Regular Session

Us Congress House Bill HB1691

Introduced
3/22/23  
Refer
3/22/23  
Refer
3/31/23  

Caption

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Impact

The potential impacts on state law include the reallocation of funds to prioritize Medicaid providers who serve a higher number of low-income individuals. This would involve modifications to current funding formulas and might increase state expenditures on healthcare. The bill is seen as a strategic move to bolster healthcare infrastructure at a time when many states are grappling with financial limitations and rising demands for public health services. Supporters believe this will lead to better health outcomes and reduced long-term costs for the state by preventing more severe health issues through early intervention.

Summary

House Bill 1691 addresses the funding mechanisms for Medicaid providers in the state, aiming to enhance the accessibility and quality of healthcare services for low-income residents. The bill introduces provisions that expand the eligibility criteria for funding and support for various healthcare programs, thereby intending to address gaps in service provision that have been highlighted in previous legislative sessions. Proponents of the bill argue that these changes are critical for ensuring that vulnerable populations have better access to necessary medical care, especially in underfunded areas such as rural communities.

Sentiment

Sentiment around HB1691 appears to be generally supportive among healthcare advocates, who view it as a necessary step toward improving health equity. However, concerns have been raised regarding the financial implications of increasing funding, particularly in the context of state budget constraints. While many legislators support the bill's objectives, some express cautious optimism about its feasibility, emphasizing the need for sustainable funding mechanisms to back the proposed changes. Thus, while the overarching sentiment is positive, reservations about implementation remain prevalent.

Contention

Notable points of contention include the specifics of how the funding increases will be sourced and the potential impact on other state-funded programs, such as education and transportation. Critics worry that without careful budgeting, prioritizing Medicaid providers could lead to detrimental cuts in other essential services. Additionally, there is debate on how the expanded eligibility criteria might affect the overall quality of care provided, raising questions about the capacity of existing providers to handle increased patient loads while maintaining service standards.

Companion Bills

No companion bills found.

Previously Filed As

US SB5349

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

US SB1717

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

US HB8244

Ensuring Seniors’ Access to Quality Care Act

US HB5526

Seniors’ Access to Critical Medications Act of 2024

US HB3164

Ensuring Community Access to Pharmacist Services Act

US HB7906

Strengthening State and Tribal Child Support Enforcement Act

US HB562

Improving Veterans Access to Congressional Services Act of 2023

US HB5461

Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023

US HB9135

Ensuring Airline Resiliency to Reduce Delays and Cancellations Act

US HB2533

EASE Act of 2025 Ensuring Access to Specialty care Everywhere Act of 2025

Similar Bills

US SB5349

Ensuring Patient Access to Critical Breakthrough Products Act of 2024

US SB1717

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

IL SB2439

VETS SUICIDE PREVNTION COUNCIL

MA S1538

Connecting veterans with access to breakthrough treatments

MA H4218

Connecting veterans with access to breakthrough treatments

US HB6705

Effective Screening and Testing for Tuberculosis Act

NC H727

Breakthrough Therapies Research/Advisory Act

US SB689

A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.